nodes	percent_of_prediction	percent_of_DWPC	metapath
Trimipramine—HTR2C—Sorafenib—liver cancer	0.218	0.331	CbGbCtD
Trimipramine—CYP2C19—Sorafenib—liver cancer	0.0861	0.131	CbGbCtD
Trimipramine—CYP2C9—Sorafenib—liver cancer	0.0716	0.109	CbGbCtD
Trimipramine—ABCB1—Sorafenib—liver cancer	0.0694	0.105	CbGbCtD
Trimipramine—CYP2D6—Sorafenib—liver cancer	0.0654	0.0992	CbGbCtD
Trimipramine—ABCB1—Doxorubicin—liver cancer	0.0421	0.0639	CbGbCtD
Trimipramine—CYP3A4—Sorafenib—liver cancer	0.0416	0.0631	CbGbCtD
Trimipramine—CYP2D6—Doxorubicin—liver cancer	0.0397	0.0602	CbGbCtD
Trimipramine—CYP3A4—Doxorubicin—liver cancer	0.0252	0.0383	CbGbCtD
Trimipramine—Oropharyngeal discomfort—Sorafenib—liver cancer	0.00417	0.0421	CcSEcCtD
Trimipramine—Gynaecomastia—Sorafenib—liver cancer	0.00271	0.0274	CcSEcCtD
Trimipramine—Benazepril—MTHFR—liver cancer	0.0021	0.254	CrCbGaD
Trimipramine—Erectile dysfunction—Sorafenib—liver cancer	0.00175	0.0177	CcSEcCtD
Trimipramine—Acute coronary syndrome—Sorafenib—liver cancer	0.00167	0.0169	CcSEcCtD
Trimipramine—Myocardial infarction—Sorafenib—liver cancer	0.00166	0.0168	CcSEcCtD
Trimipramine—Neuropathy peripheral—Sorafenib—liver cancer	0.00166	0.0168	CcSEcCtD
Trimipramine—Bone marrow depression—Epirubicin—liver cancer	0.00166	0.0168	CcSEcCtD
Trimipramine—Jaundice—Sorafenib—liver cancer	0.00165	0.0167	CcSEcCtD
Trimipramine—Stomatitis—Sorafenib—liver cancer	0.00165	0.0167	CcSEcCtD
Trimipramine—Bone marrow depression—Doxorubicin—liver cancer	0.00154	0.0155	CcSEcCtD
Trimipramine—Tinnitus—Sorafenib—liver cancer	0.00142	0.0143	CcSEcCtD
Trimipramine—Flushing—Sorafenib—liver cancer	0.00141	0.0143	CcSEcCtD
Trimipramine—Petechiae—Epirubicin—liver cancer	0.00136	0.0138	CcSEcCtD
Trimipramine—Arrhythmia—Sorafenib—liver cancer	0.00136	0.0137	CcSEcCtD
Trimipramine—Alopecia—Sorafenib—liver cancer	0.00135	0.0136	CcSEcCtD
Trimipramine—Dysgeusia—Sorafenib—liver cancer	0.0013	0.0131	CcSEcCtD
Trimipramine—Petechiae—Doxorubicin—liver cancer	0.00126	0.0127	CcSEcCtD
Trimipramine—Atrioventricular block—Epirubicin—liver cancer	0.00116	0.0117	CcSEcCtD
Trimipramine—Hypertension—Sorafenib—liver cancer	0.00114	0.0116	CcSEcCtD
Trimipramine—Coordination abnormal—Epirubicin—liver cancer	0.00114	0.0115	CcSEcCtD
Trimipramine—Dry mouth—Sorafenib—liver cancer	0.0011	0.0112	CcSEcCtD
Trimipramine—Clomipramine—GSTP1—liver cancer	0.00109	0.132	CrCbGaD
Trimipramine—Atrioventricular block—Doxorubicin—liver cancer	0.00107	0.0108	CcSEcCtD
Trimipramine—Thrombocytopenia—Sorafenib—liver cancer	0.00106	0.0107	CcSEcCtD
Trimipramine—Coordination abnormal—Doxorubicin—liver cancer	0.00106	0.0107	CcSEcCtD
Trimipramine—Anorexia—Sorafenib—liver cancer	0.00103	0.0104	CcSEcCtD
Trimipramine—Dyspepsia—Sorafenib—liver cancer	0.000952	0.00962	CcSEcCtD
Trimipramine—Decreased appetite—Sorafenib—liver cancer	0.000941	0.0095	CcSEcCtD
Trimipramine—Fatigue—Sorafenib—liver cancer	0.000933	0.00942	CcSEcCtD
Trimipramine—Constipation—Sorafenib—liver cancer	0.000925	0.00935	CcSEcCtD
Trimipramine—Vascular purpura—Epirubicin—liver cancer	0.00091	0.00919	CcSEcCtD
Trimipramine—Urticaria—Sorafenib—liver cancer	0.00086	0.00868	CcSEcCtD
Trimipramine—Body temperature increased—Sorafenib—liver cancer	0.000855	0.00864	CcSEcCtD
Trimipramine—Abdominal pain—Sorafenib—liver cancer	0.000855	0.00864	CcSEcCtD
Trimipramine—Purpura—Epirubicin—liver cancer	0.000844	0.00853	CcSEcCtD
Trimipramine—Vascular purpura—Doxorubicin—liver cancer	0.000842	0.0085	CcSEcCtD
Trimipramine—Cerebrovascular accident—Epirubicin—liver cancer	0.00083	0.00839	CcSEcCtD
Trimipramine—Purpura—Doxorubicin—liver cancer	0.000781	0.00789	CcSEcCtD
Trimipramine—Asthenia—Sorafenib—liver cancer	0.000776	0.00784	CcSEcCtD
Trimipramine—Cerebrovascular accident—Doxorubicin—liver cancer	0.000768	0.00776	CcSEcCtD
Trimipramine—Pruritus—Sorafenib—liver cancer	0.000766	0.00773	CcSEcCtD
Trimipramine—Ataxia—Epirubicin—liver cancer	0.000765	0.00773	CcSEcCtD
Trimipramine—Diarrhoea—Sorafenib—liver cancer	0.00074	0.00748	CcSEcCtD
Trimipramine—Dizziness—Sorafenib—liver cancer	0.000716	0.00723	CcSEcCtD
Trimipramine—Ataxia—Doxorubicin—liver cancer	0.000708	0.00715	CcSEcCtD
Trimipramine—Eosinophilia—Epirubicin—liver cancer	0.000696	0.00703	CcSEcCtD
Trimipramine—Vomiting—Sorafenib—liver cancer	0.000688	0.00695	CcSEcCtD
Trimipramine—Rash—Sorafenib—liver cancer	0.000682	0.00689	CcSEcCtD
Trimipramine—Dermatitis—Sorafenib—liver cancer	0.000682	0.00689	CcSEcCtD
Trimipramine—Headache—Sorafenib—liver cancer	0.000678	0.00685	CcSEcCtD
Trimipramine—Pancytopenia—Epirubicin—liver cancer	0.000668	0.00675	CcSEcCtD
Trimipramine—Pollakiuria—Epirubicin—liver cancer	0.00065	0.00656	CcSEcCtD
Trimipramine—Eosinophilia—Doxorubicin—liver cancer	0.000644	0.00651	CcSEcCtD
Trimipramine—Nausea—Sorafenib—liver cancer	0.000643	0.00649	CcSEcCtD
Trimipramine—Weight increased—Epirubicin—liver cancer	0.00064	0.00646	CcSEcCtD
Trimipramine—Drowsiness—Epirubicin—liver cancer	0.000627	0.00633	CcSEcCtD
Trimipramine—Pancytopenia—Doxorubicin—liver cancer	0.000618	0.00624	CcSEcCtD
Trimipramine—Neuropathy peripheral—Epirubicin—liver cancer	0.000615	0.00621	CcSEcCtD
Trimipramine—Stomatitis—Epirubicin—liver cancer	0.000611	0.00617	CcSEcCtD
Trimipramine—Jaundice—Epirubicin—liver cancer	0.000611	0.00617	CcSEcCtD
Trimipramine—Pollakiuria—Doxorubicin—liver cancer	0.000601	0.00607	CcSEcCtD
Trimipramine—Weight increased—Doxorubicin—liver cancer	0.000592	0.00598	CcSEcCtD
Trimipramine—Agranulocytosis—Epirubicin—liver cancer	0.000585	0.00591	CcSEcCtD
Trimipramine—Drowsiness—Doxorubicin—liver cancer	0.00058	0.00586	CcSEcCtD
Trimipramine—Neuropathy peripheral—Doxorubicin—liver cancer	0.000569	0.00574	CcSEcCtD
Trimipramine—Jaundice—Doxorubicin—liver cancer	0.000565	0.00571	CcSEcCtD
Trimipramine—Stomatitis—Doxorubicin—liver cancer	0.000565	0.00571	CcSEcCtD
Trimipramine—Hypoaesthesia—Epirubicin—liver cancer	0.00056	0.00566	CcSEcCtD
Trimipramine—Nortriptyline—CYP2E1—liver cancer	0.000545	0.066	CrCbGaD
Trimipramine—Agranulocytosis—Doxorubicin—liver cancer	0.000541	0.00547	CcSEcCtD
Trimipramine—Oxcarbazepine—ALB—liver cancer	0.000534	0.0646	CrCbGaD
Trimipramine—Tinnitus—Epirubicin—liver cancer	0.000525	0.0053	CcSEcCtD
Trimipramine—Flushing—Epirubicin—liver cancer	0.000522	0.00528	CcSEcCtD
Trimipramine—Hypoaesthesia—Doxorubicin—liver cancer	0.000518	0.00523	CcSEcCtD
Trimipramine—Arrhythmia—Epirubicin—liver cancer	0.000503	0.00508	CcSEcCtD
Trimipramine—Methotrimeprazine—CYP2E1—liver cancer	0.000502	0.0607	CrCbGaD
Trimipramine—Alopecia—Epirubicin—liver cancer	0.000497	0.00502	CcSEcCtD
Trimipramine—Tinnitus—Doxorubicin—liver cancer	0.000486	0.00491	CcSEcCtD
Trimipramine—Flushing—Doxorubicin—liver cancer	0.000483	0.00488	CcSEcCtD
Trimipramine—Dysgeusia—Epirubicin—liver cancer	0.00048	0.00485	CcSEcCtD
Trimipramine—Orphenadrine—CYP2E1—liver cancer	0.000477	0.0577	CrCbGaD
Trimipramine—Arrhythmia—Doxorubicin—liver cancer	0.000465	0.0047	CcSEcCtD
Trimipramine—Vision blurred—Epirubicin—liver cancer	0.000462	0.00466	CcSEcCtD
Trimipramine—Alopecia—Doxorubicin—liver cancer	0.00046	0.00465	CcSEcCtD
Trimipramine—Ill-defined disorder—Epirubicin—liver cancer	0.000455	0.00459	CcSEcCtD
Trimipramine—Agitation—Epirubicin—liver cancer	0.00045	0.00455	CcSEcCtD
Trimipramine—Desipramine—CYP2E1—liver cancer	0.000449	0.0543	CrCbGaD
Trimipramine—Dysgeusia—Doxorubicin—liver cancer	0.000444	0.00448	CcSEcCtD
Trimipramine—Malaise—Epirubicin—liver cancer	0.000442	0.00446	CcSEcCtD
Trimipramine—Palpitations—Epirubicin—liver cancer	0.000433	0.00437	CcSEcCtD
Trimipramine—Vision blurred—Doxorubicin—liver cancer	0.000427	0.00432	CcSEcCtD
Trimipramine—Convulsion—Epirubicin—liver cancer	0.000425	0.00429	CcSEcCtD
Trimipramine—Hypertension—Epirubicin—liver cancer	0.000423	0.00427	CcSEcCtD
Trimipramine—Ill-defined disorder—Doxorubicin—liver cancer	0.000421	0.00425	CcSEcCtD
Trimipramine—Agitation—Doxorubicin—liver cancer	0.000417	0.00421	CcSEcCtD
Trimipramine—Anxiety—Epirubicin—liver cancer	0.000416	0.0042	CcSEcCtD
Trimipramine—Discomfort—Epirubicin—liver cancer	0.000412	0.00416	CcSEcCtD
Trimipramine—Malaise—Doxorubicin—liver cancer	0.000409	0.00413	CcSEcCtD
Trimipramine—Dry mouth—Epirubicin—liver cancer	0.000408	0.00412	CcSEcCtD
Trimipramine—Confusional state—Epirubicin—liver cancer	0.000403	0.00407	CcSEcCtD
Trimipramine—Acepromazine—ALB—liver cancer	0.000403	0.0488	CrCbGaD
Trimipramine—Palpitations—Doxorubicin—liver cancer	0.000401	0.00405	CcSEcCtD
Trimipramine—Oedema—Epirubicin—liver cancer	0.0004	0.00404	CcSEcCtD
Trimipramine—Convulsion—Doxorubicin—liver cancer	0.000393	0.00397	CcSEcCtD
Trimipramine—Thrombocytopenia—Epirubicin—liver cancer	0.000392	0.00396	CcSEcCtD
Trimipramine—Hypertension—Doxorubicin—liver cancer	0.000391	0.00395	CcSEcCtD
Trimipramine—Tachycardia—Epirubicin—liver cancer	0.00039	0.00394	CcSEcCtD
Trimipramine—Anxiety—Doxorubicin—liver cancer	0.000385	0.00389	CcSEcCtD
Trimipramine—Chlorpromazine—CYP2E1—liver cancer	0.000383	0.0463	CrCbGaD
Trimipramine—Discomfort—Doxorubicin—liver cancer	0.000381	0.00385	CcSEcCtD
Trimipramine—Anorexia—Epirubicin—liver cancer	0.000381	0.00385	CcSEcCtD
Trimipramine—Imipramine—CYP2E1—liver cancer	0.000381	0.0461	CrCbGaD
Trimipramine—Amitriptyline—CYP2E1—liver cancer	0.000378	0.0458	CrCbGaD
Trimipramine—Dry mouth—Doxorubicin—liver cancer	0.000377	0.00381	CcSEcCtD
Trimipramine—Hypotension—Epirubicin—liver cancer	0.000374	0.00377	CcSEcCtD
Trimipramine—Confusional state—Doxorubicin—liver cancer	0.000373	0.00377	CcSEcCtD
Trimipramine—Oedema—Doxorubicin—liver cancer	0.00037	0.00374	CcSEcCtD
Trimipramine—Thrombocytopenia—Doxorubicin—liver cancer	0.000362	0.00366	CcSEcCtD
Trimipramine—Insomnia—Epirubicin—liver cancer	0.000362	0.00365	CcSEcCtD
Trimipramine—Tachycardia—Doxorubicin—liver cancer	0.000361	0.00365	CcSEcCtD
Trimipramine—Paraesthesia—Epirubicin—liver cancer	0.000359	0.00363	CcSEcCtD
Trimipramine—Somnolence—Epirubicin—liver cancer	0.000355	0.00359	CcSEcCtD
Trimipramine—Anorexia—Doxorubicin—liver cancer	0.000353	0.00356	CcSEcCtD
Trimipramine—Dyspepsia—Epirubicin—liver cancer	0.000352	0.00356	CcSEcCtD
Trimipramine—Decreased appetite—Epirubicin—liver cancer	0.000348	0.00351	CcSEcCtD
Trimipramine—Hypotension—Doxorubicin—liver cancer	0.000346	0.00349	CcSEcCtD
Trimipramine—Fatigue—Epirubicin—liver cancer	0.000345	0.00348	CcSEcCtD
Trimipramine—Constipation—Epirubicin—liver cancer	0.000342	0.00345	CcSEcCtD
Trimipramine—Insomnia—Doxorubicin—liver cancer	0.000335	0.00338	CcSEcCtD
Trimipramine—Paraesthesia—Doxorubicin—liver cancer	0.000332	0.00336	CcSEcCtD
Trimipramine—Feeling abnormal—Epirubicin—liver cancer	0.00033	0.00333	CcSEcCtD
Trimipramine—Somnolence—Doxorubicin—liver cancer	0.000329	0.00332	CcSEcCtD
Trimipramine—Dyspepsia—Doxorubicin—liver cancer	0.000326	0.00329	CcSEcCtD
Trimipramine—Decreased appetite—Doxorubicin—liver cancer	0.000322	0.00325	CcSEcCtD
Trimipramine—Fatigue—Doxorubicin—liver cancer	0.000319	0.00322	CcSEcCtD
Trimipramine—Urticaria—Epirubicin—liver cancer	0.000318	0.00321	CcSEcCtD
Trimipramine—Constipation—Doxorubicin—liver cancer	0.000316	0.0032	CcSEcCtD
Trimipramine—Body temperature increased—Epirubicin—liver cancer	0.000316	0.00319	CcSEcCtD
Trimipramine—Abdominal pain—Epirubicin—liver cancer	0.000316	0.00319	CcSEcCtD
Trimipramine—Clomipramine—ALB—liver cancer	0.000306	0.0371	CrCbGaD
Trimipramine—Feeling abnormal—Doxorubicin—liver cancer	0.000305	0.00308	CcSEcCtD
Trimipramine—Nortriptyline—ALB—liver cancer	0.000299	0.0362	CrCbGaD
Trimipramine—Urticaria—Doxorubicin—liver cancer	0.000294	0.00297	CcSEcCtD
Trimipramine—Abdominal pain—Doxorubicin—liver cancer	0.000292	0.00295	CcSEcCtD
Trimipramine—Body temperature increased—Doxorubicin—liver cancer	0.000292	0.00295	CcSEcCtD
Trimipramine—Asthenia—Epirubicin—liver cancer	0.000287	0.0029	CcSEcCtD
Trimipramine—Pruritus—Epirubicin—liver cancer	0.000283	0.00286	CcSEcCtD
Trimipramine—Diarrhoea—Epirubicin—liver cancer	0.000274	0.00276	CcSEcCtD
Trimipramine—Asthenia—Doxorubicin—liver cancer	0.000265	0.00268	CcSEcCtD
Trimipramine—Dizziness—Epirubicin—liver cancer	0.000264	0.00267	CcSEcCtD
Trimipramine—Pruritus—Doxorubicin—liver cancer	0.000262	0.00264	CcSEcCtD
Trimipramine—Vomiting—Epirubicin—liver cancer	0.000254	0.00257	CcSEcCtD
Trimipramine—Diarrhoea—Doxorubicin—liver cancer	0.000253	0.00256	CcSEcCtD
Trimipramine—Rash—Epirubicin—liver cancer	0.000252	0.00255	CcSEcCtD
Trimipramine—Dermatitis—Epirubicin—liver cancer	0.000252	0.00254	CcSEcCtD
Trimipramine—Headache—Epirubicin—liver cancer	0.000251	0.00253	CcSEcCtD
Trimipramine—Dizziness—Doxorubicin—liver cancer	0.000245	0.00247	CcSEcCtD
Trimipramine—Nausea—Epirubicin—liver cancer	0.000238	0.0024	CcSEcCtD
Trimipramine—Vomiting—Doxorubicin—liver cancer	0.000235	0.00238	CcSEcCtD
Trimipramine—Rash—Doxorubicin—liver cancer	0.000233	0.00236	CcSEcCtD
Trimipramine—Dermatitis—Doxorubicin—liver cancer	0.000233	0.00235	CcSEcCtD
Trimipramine—Headache—Doxorubicin—liver cancer	0.000232	0.00234	CcSEcCtD
Trimipramine—Nausea—Doxorubicin—liver cancer	0.00022	0.00222	CcSEcCtD
Trimipramine—Chlorpromazine—ALB—liver cancer	0.00021	0.0254	CrCbGaD
Trimipramine—Amitriptyline—ALB—liver cancer	0.000208	0.0251	CrCbGaD
Trimipramine—HRH1—Signaling by GPCR—PIK3CA—liver cancer	1.55e-05	6.65e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—KRAS—liver cancer	1.55e-05	6.65e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—JUN—liver cancer	1.55e-05	6.64e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—CTNNB1—liver cancer	1.55e-05	6.63e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—RAF1—liver cancer	1.54e-05	6.62e-05	CbGpPWpGaD
Trimipramine—ADRA1B—GPCR downstream signaling—AKT1—liver cancer	1.54e-05	6.61e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—RAF1—liver cancer	1.54e-05	6.6e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling by GPCR—KRAS—liver cancer	1.54e-05	6.6e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—CTNNB1—liver cancer	1.54e-05	6.59e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—PIK3CB—liver cancer	1.53e-05	6.56e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—MTOR—liver cancer	1.53e-05	6.56e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—CASP3—liver cancer	1.53e-05	6.55e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—MAPK8—liver cancer	1.53e-05	6.55e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—IL2—liver cancer	1.53e-05	6.54e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling by GPCR—AKT1—liver cancer	1.52e-05	6.53e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling by GPCR—PIK3CA—liver cancer	1.52e-05	6.53e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling by GPCR—IL6—liver cancer	1.52e-05	6.51e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—MMP9—liver cancer	1.52e-05	6.5e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—PIK3CG—liver cancer	1.52e-05	6.5e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—CYCS—liver cancer	1.52e-05	6.5e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—RAF1—liver cancer	1.51e-05	6.48e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—CDKN1A—liver cancer	1.51e-05	6.47e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—MMP9—liver cancer	1.51e-05	6.46e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—MTOR—liver cancer	1.51e-05	6.46e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—PIK3CB—liver cancer	1.51e-05	6.46e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—MTOR—liver cancer	1.5e-05	6.44e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—PIK3CB—liver cancer	1.5e-05	6.44e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—CDKN1A—liver cancer	1.5e-05	6.44e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—GOT1—liver cancer	1.49e-05	6.37e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—GGT1—liver cancer	1.49e-05	6.37e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—CCND1—liver cancer	1.49e-05	6.37e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—JUN—liver cancer	1.48e-05	6.36e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—PIK3CG—liver cancer	1.48e-05	6.34e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—MTOR—liver cancer	1.48e-05	6.32e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—PIK3CB—liver cancer	1.48e-05	6.32e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—MAPK8—liver cancer	1.47e-05	6.32e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—CTNNB1—liver cancer	1.47e-05	6.31e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling by GPCR—AKT1—liver cancer	1.47e-05	6.3e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—MAPK8—liver cancer	1.47e-05	6.29e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—PPARG—liver cancer	1.46e-05	6.27e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling by GPCR—AKT1—liver cancer	1.46e-05	6.27e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling by GPCR—HRAS—liver cancer	1.46e-05	6.27e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.45e-05	6.21e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—MMP9—liver cancer	1.44e-05	6.19e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling by GPCR—HRAS—liver cancer	1.44e-05	6.17e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—CDKN1A—liver cancer	1.44e-05	6.17e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—CDKN1B—liver cancer	1.44e-05	6.16e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling by GPCR—HRAS—liver cancer	1.44e-05	6.15e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—PPARG—liver cancer	1.43e-05	6.12e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—PIK3CA—liver cancer	1.43e-05	6.11e-05	CbGpPWpGaD
Trimipramine—DRD2—GPCR downstream signaling—AKT1—liver cancer	1.42e-05	6.09e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling by GPCR—PIK3CA—liver cancer	1.41e-05	6.06e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—CDKN1B—liver cancer	1.41e-05	6.06e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—CDKN1B—liver cancer	1.41e-05	6.05e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—VEGFA—liver cancer	1.41e-05	6.04e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling by GPCR—HRAS—liver cancer	1.41e-05	6.04e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—CASP3—liver cancer	1.41e-05	6.04e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—IL2—liver cancer	1.41e-05	6.03e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—MAPK8—liver cancer	1.4e-05	6.02e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—RAF1—liver cancer	1.4e-05	6.02e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling by GPCR—AKT1—liver cancer	1.4e-05	6e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling by GPCR—IL6—liver cancer	1.4e-05	6e-05	CbGpPWpGaD
Trimipramine—HTR2A—GPCR downstream signaling—AKT1—liver cancer	1.4e-05	6e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—STAT3—liver cancer	1.4e-05	5.98e-05	CbGpPWpGaD
Trimipramine—HRH1—GPCR downstream signaling—AKT1—liver cancer	1.4e-05	5.98e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—PIK3CG—liver cancer	1.39e-05	5.98e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—CASP3—liver cancer	1.39e-05	5.94e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—CDKN1B—liver cancer	1.38e-05	5.93e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—IL2—liver cancer	1.38e-05	5.93e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—CASP3—liver cancer	1.38e-05	5.93e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—PIK3CG—liver cancer	1.38e-05	5.92e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—IL2—liver cancer	1.38e-05	5.92e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—TP53—liver cancer	1.38e-05	5.91e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling by GPCR—IL6—liver cancer	1.38e-05	5.9e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling by GPCR—IL6—liver cancer	1.37e-05	5.89e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—CCND1—liver cancer	1.37e-05	5.88e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—PIK3CB—liver cancer	1.37e-05	5.88e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—MTOR—liver cancer	1.37e-05	5.88e-05	CbGpPWpGaD
Trimipramine—ADRA1A—GPCR downstream signaling—AKT1—liver cancer	1.37e-05	5.87e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—JUN—liver cancer	1.37e-05	5.86e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—VEGFA—liver cancer	1.36e-05	5.83e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—CTNNB1—liver cancer	1.36e-05	5.82e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—CASP3—liver cancer	1.36e-05	5.82e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—IL2—liver cancer	1.36e-05	5.81e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—VEGFA—liver cancer	1.35e-05	5.8e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—CCND1—liver cancer	1.35e-05	5.78e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling by GPCR—IL6—liver cancer	1.35e-05	5.78e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—STAT3—liver cancer	1.35e-05	5.78e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—JUN—liver cancer	1.35e-05	5.77e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—CCND1—liver cancer	1.35e-05	5.77e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—PPARG—liver cancer	1.35e-05	5.77e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—JUN—liver cancer	1.34e-05	5.76e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—STAT3—liver cancer	1.34e-05	5.75e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—CTNNB1—liver cancer	1.34e-05	5.73e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—GSTP1—liver cancer	1.34e-05	5.73e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—PPARG—liver cancer	1.33e-05	5.72e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—CTNNB1—liver cancer	1.33e-05	5.71e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—PIK3CD—liver cancer	1.33e-05	5.71e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—MMP9—liver cancer	1.33e-05	5.71e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—CDKN1A—liver cancer	1.33e-05	5.68e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—CCND1—liver cancer	1.32e-05	5.66e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—HRAS—liver cancer	1.32e-05	5.65e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—JUN—liver cancer	1.32e-05	5.65e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—HMOX1—liver cancer	1.32e-05	5.65e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—ALB—liver cancer	1.32e-05	5.64e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—MMP9—liver cancer	1.31e-05	5.61e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling by GPCR—HRAS—liver cancer	1.31e-05	5.61e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—CTNNB1—liver cancer	1.31e-05	5.61e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—MMP9—liver cancer	1.31e-05	5.6e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—CDKN1A—liver cancer	1.31e-05	5.59e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—CDKN1A—liver cancer	1.3e-05	5.58e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—PIK3CD—liver cancer	1.3e-05	5.57e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—MYC—liver cancer	1.3e-05	5.56e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—VEGFA—liver cancer	1.3e-05	5.56e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—MAPK8—liver cancer	1.29e-05	5.55e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—TGFB1—liver cancer	1.29e-05	5.55e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling by GPCR—AKT1—liver cancer	1.29e-05	5.53e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—CDKN1B—liver cancer	1.29e-05	5.51e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—ALB—liver cancer	1.28e-05	5.5e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—STAT3—liver cancer	1.28e-05	5.5e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—MMP9—liver cancer	1.28e-05	5.5e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—CDKN1A—liver cancer	1.28e-05	5.48e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—MAPK8—liver cancer	1.27e-05	5.46e-05	CbGpPWpGaD
Trimipramine—ADRA2A—GPCR downstream signaling—AKT1—liver cancer	1.27e-05	5.45e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—MAPK8—liver cancer	1.27e-05	5.45e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling by GPCR—AKT1—liver cancer	1.27e-05	5.44e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling by GPCR—AKT1—liver cancer	1.27e-05	5.43e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—IL6—liver cancer	1.26e-05	5.41e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—CASP3—liver cancer	1.26e-05	5.4e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—IL2—liver cancer	1.26e-05	5.4e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling by GPCR—IL6—liver cancer	1.25e-05	5.37e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—MYC—liver cancer	1.25e-05	5.37e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—TGFB1—liver cancer	1.25e-05	5.36e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—MAPK8—liver cancer	1.25e-05	5.35e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—MYC—liver cancer	1.25e-05	5.34e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling by GPCR—AKT1—liver cancer	1.24e-05	5.33e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—TGFB1—liver cancer	1.24e-05	5.33e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—GSTM1—liver cancer	1.23e-05	5.26e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—CCND1—liver cancer	1.23e-05	5.26e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—PIK3CD—liver cancer	1.23e-05	5.25e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—JUN—liver cancer	1.22e-05	5.25e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—CTNNB1—liver cancer	1.22e-05	5.21e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—PIK3CD—liver cancer	1.22e-05	5.21e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—ALB—liver cancer	1.21e-05	5.19e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—ALB—liver cancer	1.2e-05	5.14e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—KRAS—liver cancer	1.2e-05	5.14e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—VEGFA—liver cancer	1.2e-05	5.12e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—MYC—liver cancer	1.19e-05	5.11e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—MMP9—liver cancer	1.19e-05	5.11e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—TGFB1—liver cancer	1.19e-05	5.1e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—CDKN1A—liver cancer	1.19e-05	5.09e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—STAT3—liver cancer	1.18e-05	5.07e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—VEGFA—liver cancer	1.18e-05	5.04e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—VEGFA—liver cancer	1.17e-05	5.03e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—AKT1—liver cancer	1.16e-05	4.99e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—STAT3—liver cancer	1.16e-05	4.99e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—CYP1A1—liver cancer	1.16e-05	4.99e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—STAT3—liver cancer	1.16e-05	4.98e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—PIK3CB—liver cancer	1.16e-05	4.98e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—MAPK8—liver cancer	1.16e-05	4.97e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—KRAS—liver cancer	1.16e-05	4.96e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling by GPCR—AKT1—liver cancer	1.16e-05	4.95e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—VEGFA—liver cancer	1.15e-05	4.94e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—KRAS—liver cancer	1.15e-05	4.93e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—STAT3—liver cancer	1.14e-05	4.89e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—PIK3CB—liver cancer	1.13e-05	4.86e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—KRAS—liver cancer	1.1e-05	4.72e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—PIK3CA—liver cancer	1.1e-05	4.72e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—MYC—liver cancer	1.1e-05	4.71e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—TGFB1—liver cancer	1.1e-05	4.7e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—MTHFR—liver cancer	1.08e-05	4.65e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—MYC—liver cancer	1.08e-05	4.64e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—MYC—liver cancer	1.08e-05	4.63e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—TGFB1—liver cancer	1.08e-05	4.63e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—TGFB1—liver cancer	1.08e-05	4.62e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—VEGFA—liver cancer	1.07e-05	4.59e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—PIK3CB—liver cancer	1.07e-05	4.58e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—TP53—liver cancer	1.07e-05	4.57e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PPARA—liver cancer	1.06e-05	4.56e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—PIK3CA—liver cancer	1.06e-05	4.56e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—MYC—liver cancer	1.06e-05	4.54e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—STAT3—liver cancer	1.06e-05	4.54e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—PIK3CB—liver cancer	1.06e-05	4.54e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—PIK3CA—liver cancer	1.06e-05	4.53e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—TGFB1—liver cancer	1.06e-05	4.53e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—TP53—liver cancer	1.03e-05	4.41e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—TP53—liver cancer	1.02e-05	4.39e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—HRAS—liver cancer	1.02e-05	4.37e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—KRAS—liver cancer	1.02e-05	4.36e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—PIK3CA—liver cancer	1.01e-05	4.34e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—KRAS—liver cancer	1e-05	4.29e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Metabolism—PIK3CA—liver cancer	9.99e-06	4.28e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—KRAS—liver cancer	9.98e-06	4.28e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—MYC—liver cancer	9.84e-06	4.22e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—HRAS—liver cancer	9.84e-06	4.22e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—TGFB1—liver cancer	9.82e-06	4.21e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—TP53—liver cancer	9.8e-06	4.2e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—KRAS—liver cancer	9.79e-06	4.2e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—HRAS—liver cancer	9.79e-06	4.19e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—IL6—liver cancer	9.75e-06	4.18e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—IL6—liver cancer	9.42e-06	4.04e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—HRAS—liver cancer	9.37e-06	4.02e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—IL6—liver cancer	9.37e-06	4.01e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—PIK3CA—liver cancer	9.34e-06	4e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—PIK3CA—liver cancer	9.19e-06	3.94e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—PIK3CA—liver cancer	9.17e-06	3.93e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PIK3CG—liver cancer	9.12e-06	3.91e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—KRAS—liver cancer	9.1e-06	3.9e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—TP53—liver cancer	9.03e-06	3.87e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—AKT1—liver cancer	9e-06	3.86e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—PIK3CA—liver cancer	8.99e-06	3.86e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—IL6—liver cancer	8.97e-06	3.84e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—TP53—liver cancer	8.89e-06	3.81e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—TP53—liver cancer	8.87e-06	3.8e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PPARG—liver cancer	8.8e-06	3.77e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—TP53—liver cancer	8.7e-06	3.73e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—AKT1—liver cancer	8.69e-06	3.72e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—AKT1—liver cancer	8.64e-06	3.7e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—HRAS—liver cancer	8.64e-06	3.7e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—HRAS—liver cancer	8.5e-06	3.64e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—HRAS—liver cancer	8.48e-06	3.63e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—PIK3CA—liver cancer	8.36e-06	3.58e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—HRAS—liver cancer	8.32e-06	3.57e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—AKT1—liver cancer	8.27e-06	3.55e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—IL6—liver cancer	8.27e-06	3.54e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Metabolism—AKT1—liver cancer	8.16e-06	3.5e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—IL6—liver cancer	8.13e-06	3.49e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—IL6—liver cancer	8.12e-06	3.48e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—TP53—liver cancer	8.08e-06	3.47e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PIK3CD—liver cancer	8.01e-06	3.43e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—IL6—liver cancer	7.96e-06	3.41e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—ALB—liver cancer	7.91e-06	3.39e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—HRAS—liver cancer	7.73e-06	3.31e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—AKT1—liver cancer	7.63e-06	3.27e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—AKT1—liver cancer	7.5e-06	3.22e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—AKT1—liver cancer	7.49e-06	3.21e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—IL6—liver cancer	7.4e-06	3.17e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—AKT1—liver cancer	7.35e-06	3.15e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—PIK3CA—liver cancer	7.08e-06	3.03e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PIK3CB—liver cancer	6.98e-06	2.99e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—PIK3CA—liver cancer	6.91e-06	2.96e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—AKT1—liver cancer	6.83e-06	2.93e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—PIK3CA—liver cancer	6.51e-06	2.79e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—PIK3CA—liver cancer	6.46e-06	2.77e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—AKT1—liver cancer	5.78e-06	2.48e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—AKT1—liver cancer	5.65e-06	2.42e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—AKT1—liver cancer	5.32e-06	2.28e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—AKT1—liver cancer	5.27e-06	2.26e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PIK3CA—liver cancer	4.26e-06	1.83e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—AKT1—liver cancer	3.48e-06	1.49e-05	CbGpPWpGaD
